Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
2.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
3.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

4.

Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex.

Schön T, Matuschek E, Mohamed S, Utukuri M, Heysell S, Alffenaar JW, Shin S, Martinez E, Sintchenko V, Maurer FP, Keller PM, Kahlmeter G, Köser CU.

Clin Microbiol Infect. 2019 Apr;25(4):403-405. doi: 10.1016/j.cmi.2019.01.019. Epub 2019 Feb 14. No abstract available.

PMID:
30771527
5.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

6.

Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

Akkerman OW, Alffenaar JWC.

J Antimicrob Chemother. 2019 Mar 1;74(3):834. doi: 10.1093/jac/dky490. No abstract available.

PMID:
30508093
7.

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.

Dekkers BGJ, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e02074-18. doi: 10.1128/AAC.02074-18. Print 2019 Feb. No abstract available.

8.

Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study.

Pradipta IS, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JWC, Hak E.

Clin Microbiol Infect. 2019 Jun;25(6):761.e1-761.e7. doi: 10.1016/j.cmi.2018.10.009. Epub 2018 Oct 27.

PMID:
30394362
9.

Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.

Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW.

J Infect. 2018 Dec;77(6):469-478. doi: 10.1016/j.jinf.2018.10.004. Epub 2018 Oct 16.

PMID:
30339803
10.

Global TB Network: working together to eliminate tuberculosis.

Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, Migliori GB.

J Bras Pneumol. 2018 Set-Oct;44(5):347-349. doi: 10.1590/S1806-37562018000000279. English, Portuguese. No abstract available.

11.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

12.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
13.

Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.

Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):991-999. doi: 10.5588/ijtld.17.0523.

PMID:
30092863
14.

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.

Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW.

Br J Clin Pharmacol. 2018 Dec;84(12):2747-2760. doi: 10.1111/bcp.13722. Epub 2018 Oct 3. Review.

15.

Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.

Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C.

Int J Antimicrob Agents. 2018 Jul;52(1):109-113. doi: 10.1016/j.ijantimicag.2018.04.020. Epub 2018 May 8.

PMID:
29751121
16.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

17.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

18.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

19.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

20.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

21.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.

Alffenaar JWC, Peloquin CA, Migliori GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. No abstract available.

PMID:
29297417
22.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

23.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

24.

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.

Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Lashof AMLO, Groeneveld GH, van der Hoeven J, Alffenaar JWC, Russel FGM, van de Veerdonk F, Brüggemann RJM.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00915-17. doi: 10.1128/AAC.00915-17. Print 2017 Sep.

25.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

26.

Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.

Aardema H, Nannan Panday P, Wessels M, van Hateren K, Dieperink W, Kosterink JGW, Alffenaar JW, Zijlstra JG.

Int J Antimicrob Agents. 2017 Jul;50(1):68-73. doi: 10.1016/j.ijantimicag.2017.02.020. Epub 2017 May 10.

PMID:
28501674
27.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

28.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01400-16. doi: 10.1128/AAC.01400-16. Print 2017 Mar.

29.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

30.

Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.

Nguyen TV, Cao TB, Akkerman OW, Tiberi S, Vu DH, Alffenaar JW.

Expert Rev Clin Pharmacol. 2016 Aug;9(8):1025-37. doi: 10.1080/17512433.2016.1200462. Epub 2016 Jun 27. Review.

PMID:
27322153
31.

Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.

Zuur MA, Akkerman OW, Touw DJ, van der Werf TS, Cobelens F, Burger DM, Grobusch MP, Alffenaar JW.

Eur Respir J. 2016 Sep;48(3):932-4. doi: 10.1183/13993003.00599-2016. Epub 2016 Jun 10. No abstract available.

32.

Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Wilffert B, Touw DJ, Alffenaar JW.

J Antimicrob Chemother. 2016 Oct;71(10):2691-703. doi: 10.1093/jac/dkw164. Epub 2016 May 26. Review.

PMID:
27231277
33.

Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit.

Dijkstra JA, Voerman AJ, Greijdanus B, Touw DJ, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4646-51. doi: 10.1128/AAC.03025-15. Print 2016 Aug.

34.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

35.

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Alsaad N, Dijkstra JA, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3942-7. doi: 10.1128/AAC.02175-15. Print 2016 Jul.

36.

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1288-90. doi: 10.1183/13993003.02185-2015. No abstract available.

37.

Reply to Verhaeghe et al.

Akkerman OW, van Hateren K, Koster RA, Luijckx GJ, van der Werf TS, Alffenaar JW.

Clin Infect Dis. 2016 Jul 1;63(1):146-7. doi: 10.1093/cid/ciw165. Epub 2016 Mar 29. No abstract available.

PMID:
27025830
38.

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17. No abstract available.

39.

Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.

Cattaneo D, Alffenaar JW, Neely M.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):533-44. doi: 10.1517/17425255.2016.1166204. Epub 2016 Mar 28. Review.

PMID:
26982718
40.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

41.

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.

Hoppentocht M, Akkerman OW, Hagedoorn P, Alffenaar JW, van der Werf TS, Kerstjens HA, Frijlink HW, de Boer AH.

PLoS One. 2016 Mar 9;11(3):e0149768. doi: 10.1371/journal.pone.0149768. eCollection 2016.

42.

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):509-21. doi: 10.1517/17425255.2016.1162785. Epub 2016 Mar 24. Review.

PMID:
26950189
43.

Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.

Srivastava S, van Rijn SP, Wessels AM, Alffenaar JW, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3193-5. doi: 10.1128/AAC.02924-15. Print 2016 May.

44.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
45.

Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.

Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2727-31. doi: 10.1128/AAC.02830-15. Print 2016 May.

46.

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

Hofman S, Segers MM, Ghimire S, Bolhuis MS, Sturkenboom MG, Van Soolingen D, Alffenaar JW.

Expert Opin Emerg Drugs. 2016;21(1):103-16. doi: 10.1517/14728214.2016.1151000. Epub 2016 Feb 20. Review.

PMID:
26848966
47.

Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.

van Wanrooy MJ, Rodgers MG, Span LF, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Ther Drug Monit. 2016 Jun;38(3):313-8. doi: 10.1097/FTD.0000000000000284.

PMID:
26845112
48.

Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.

Huurneman LJ, Neely M, Veringa A, Docobo Pérez F, Ramos-Martin V, Tissing WJ, Alffenaar JW, Hope W.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2336-42. doi: 10.1128/AAC.03023-15. Print 2016 Apr.

49.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

50.

Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.

van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1229-34. doi: 10.1183/13993003.01654-2015. Epub 2016 Jan 7.

Supplemental Content

Loading ...
Support Center